1. Overview of Apheresis Market Valuation & Projections to 2035

The global Apheresis Market equipment segment exhibits strong growth, driven by rising demand in therapeutic and donation settings. Estimates vary based on forecast sources:

• Metatech Insights: Market grows from USD 3.28 billion (2024) to USD 8.72 billion by 2035 at a CAGR of 9.3% .

• Precedence Research: Projected to expand from USD 3.51 billion (2025) to USD 7.77 billion by 2034, with a 9.24% CAGR .

• A more conservative forecast (PharmiWeb) values the market at USD 2.01 million (2023)—likely a reporting error—so lower reliability .

Consensus: equipment revenues will more than double by 2035, with consistent CAGR around 9%. Equipment makes up a minority share compared to consumables, which form a recurring revenue base.

2. Technology Comparison: Centrifugation vs Membrane Filtration

A. Centrifugation Technologies

Centrifugation remains the dominant apheresis method:

• Holds approx. 58–67% market share in 2022 .

• Offers continuous- and intermittent-flow platforms, enabling efficient separation and returning of blood components .

Strengths:

• High throughput and automation.

• Mature technology with established device families (Terumo BCT, Haemonetics).

• Optimal for platelet and red-cell processing, especially in donor environments.

Challenges:

• Requires larger machines and infrastructure.

• Operator training and maintenance are more complex.

• High extracorporeal volumes (particularly in intermittent systems) may limit use in vulnerable populations .

B. Membrane Filtration Technologies

Membrane filtration is the emerging alternative:

• Smaller base (~30–40% share), but growing fast .

• Enables selective separation, e.g. LDL apheresis and immunoadsorption.

• Generates lower extracorporeal volumes, beneficial for pediatric, elderly, and cardiac-compromised patients.

Strengths:

• Compact systems, simpler to deploy.

• Effective in selective therapies (LDL, immune disorders).

• Lower extracorporeal blood volumes enhance safety and comfort.

Challenges:

• Generally slower throughput, capacity limits.

• Consumables (filter kits) may be more costly per procedure.

• Less automation; many systems are semi-automated or manual.

C. Comparative Dynamics

• Volume vs specificity: Centrifugation excels in volume-driven donation scenarios, while membrane filtration suits targeted clinical uses.

• Automation vs precision: Centrifugation platforms deliver robust automation, whereas membrane systems cater to specialised, selective processing.

• Device vs consumable interplay: Devices are a one-time investment; consumables drive the recurring revenue. Membrane filtration often relies on high-value filter kits.

3. Market Segment Forecasts by Technology

While specific forecasts by technology are less common, broader data contextualises trends:

• Total equipment market (~USD 3.3 billion in 2024) is expected to reach USD 8.7 billion by 2035 with ~9.3% CAGR.

• Therapeutic apheresis segment grows from USD 2.92 billion (2025) to USD 4.28 billion (2035), at a 3.9% CAGR .

• Therapeutic apheresis consumables drove ~$1.3 billion in 2023, forecast to hit $2.8 billion by 2035 at 6.7% CAGR .

• Plasmapheresis (centrifuge-based) is projected from USD 1.34 billion (2024) to USD 2.97 billion by 2035, at ~7.6–7.8% CAGR .

Together, centrifugation-based plasmapheresis supports substantial growth (~7–8% CAGR), underpinning broader equipment projections (9% CAGR). Membrane filtration growth is embedded in therapeutic device expansion; emerging use-cases (e.g., LDL immunoadsorption) and pediatric demand fuel above-average CAGR.

4. Drivers Behind Technology Adoption

• Clinical demand: Rising autoimmune, cardiovascular, neurological, hematological conditions propel both plasmapheresis and selective apheresis.

• Therapy personalization: Membrane systems facilitate targeted filtration—critical in LDL apheresis, immune-mediated conditions, and pediatric applications.

• Automation trend: Centrifugation platforms benefit from AI integration, smart sensors, data connectivity—a driver of sustained investment and adoption.

• Infrastructure shifts: Growth in ambulatory and point-of-care settings favors compact, membrane-based systems; hospitals and donation centers still rely on centrifugation.

5. Regional Market Insights

• North America remains strongest, leading with >35% share of equipment revenue; high centrifuge penetration; membrane-based clinical niche driven by advanced healthcare 

• Asia‑Pacific is the fastest-growing region; rapid adoption of both technologies in China, India, Japan; membrane equipment gaining ground in decentralized and pediatric settings 

• Europe shows balanced use; membrane rising in Germany and UK for LDL and niche therapies; centrifugation dominating donation systems.

Technology growth mix:

• Centrifugation devices: ~9–10% CAGR.

• Membrane filtration: likely 10–12%+ CAGR fueled by clinical innovation.

6. Forecast Scenarios for 2035

By 2035:

• Centrifugation remains dominant in equipment revenue (~60%), potentially reaching USD 5 billion.

• Membrane systems close in at ~USD 3 billion from specialized uses and expanding procedure types.

7. Strategic Implications & Outlook

• Manufacturers should diversify: extend AI-enhanced centrifuge platforms alongside membrane systems optimized for niche therapies and outpatient settings.

• Consumables producers should capitalize on reusable kits and higher-cost filter lines for membrane platforms while maintaining economies in centrifuge kit production.

• Emerging markets: Asia‑Pacific offers high CAGR opportunities; membrane filtration can leapfrog traditional infrastructure constraints.

8. Final Takeaways

1. Centrifugation remains the technological and economic backbone of the apheresis market, with a projected CAGR consistent with equipment growth (≈9–10%).

2. Membrane filtration is the innovation frontier—boasting higher CAGR, expanding clinical applications, and lower extracorporeal volumes.

3. By 2035, centrifugation will likely account for ~USD 5 billion of equipment revenue, while membrane systems may reach ~USD 3 billion.